TrialMedical oncology (Northwood, London, England)2015

Rechallenge of docetaxel combined with epirubicin given on a weekly schedule in advanced castration-resistant prostate cancer patients previously exposed to docetaxel and abiraterone acetate: a single-institution experience.

R Petrioli et al.PubMed ↗Publisher ↗

No numbers read from the abstract.